Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Operating Expenses (2022 - 2026)

Sagimet Biosciences' Operating Expenses history spans 5 years, with the latest figure at $11.7 million for Q1 2026.

  • Quarterly Operating Expenses fell 41.04% to $11.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $48.7 million through Mar 2026, down 25.65% year-over-year, with the annual reading at $56.9 million for FY2025, 4.47% up from the prior year.
  • Operating Expenses came in at $11.7 million for Q1 2026, up from $10.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $19.9 million in Q1 2025 to a low of $6.8 million in Q1 2023.
  • The 5-year median for Operating Expenses is $10.0 million (2023), against an average of $11.1 million.
  • Year-over-year, Operating Expenses soared 126.56% in 2025 and then crashed 41.04% in 2026.
  • Sagimet Biosciences' Operating Expenses stood at $7.4 million in 2022, then increased by 28.13% to $9.5 million in 2023, then skyrocketed by 92.21% to $18.2 million in 2024, then tumbled by 40.84% to $10.8 million in 2025, then rose by 8.81% to $11.7 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Operating Expenses are $11.7 million (Q1 2026), $10.8 million (Q4 2025), and $14.3 million (Q3 2025).